Use of nonopioid directives authorized, and immunity for certain acts or failures to act established.
HF1379 creates a new legal mechanism in Minnesota for patients to refuse opioid treatment through a “nonopioid directive.” The bill defines who may execute the directive, including a patient with capacity or a health care agent acting on the patient’s behalf, and specifies that the directive must instruct health professionals and prescribers not to administer an opioid or offer an opioid prescription. It also requires health care providers to place a nonopioid directive, and any revocation of it, into the patient’s health care record.
The bill generally requires prescribers and health professionals to follow a valid nonopioid directive, but it creates a narrow emergency exception. In emergency circumstances, including outside a hospital or during a surgical complication, an opioid may be administered if the prescriber believes it is medically necessary and it is not practical to access the patient’s record. If an opioid is given under that exception, the patient must be informed about substance use disorder services. The bill also directs the commissioner of health to create and post a standard directive form and revocation instructions.
HF1379 amends Minnesota Statutes chapter 145C and adds new section 145C.18 to establish enforceable patient instructions against opioid use. It expands the existing framework for opioid-related instructions in health records, imposes documentation duties on providers, and grants immunity from criminal prosecution, civil liability, and professional discipline for covered health professionals, facilities, employees, and emergency medical services providers who act reasonably and in good faith when complying with, or inadvertently failing to comply with, a nonopioid directive. The bill affects patients, health care agents, prescribers, hospitals, clinics, and EMS personnel, while also requiring the Department of Health to publish a standardized form.
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears supportive and policy-driven, focused on patient autonomy and clearer clinical instructions. The bill’s authorship and progression through committee referrals suggest it was treated as a substantive health-policy measure rather than a controversial partisan proposal. No recorded floor votes or public testimony are included here to indicate broader opposition or support beyond the legislative drafting itself.
The main points of potential contention are the balance between patient autonomy and emergency medical judgment, and the scope of liability protections for providers. Some may view the directive as an important way to prevent unwanted opioid exposure, while others may be concerned that it could complicate urgent care when records are unavailable or when pain management is medically necessary. The bill addresses this by allowing emergency exceptions and by providing immunity for good-faith actions, but those same protections could also be debated by providers, patient advocates, and liability-focused stakeholders over whether they are too broad or too narrow.